However, at 39 weeks post-infection, anti-IL-17A mAb treatment significantly enhanced lung IL-4 (Fig 6I) and IL-22 (Fig 6J) levels compared to isotype-matched control Ab treatment in the lungs of M. intracellulare-infected mice. Here, IL22 is linked to infection.